Insider Selling: BioMarin Pharmaceutical (NASDAQ:BMRN) EVP Sells $381,963.88 in Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP Gregory Friberg sold 6,326 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $60.38, for a total transaction of $381,963.88. Following the transaction, the executive vice president owned 37,578 shares in the company, valued at approximately $2,268,959.64. The trade was a 14.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

BioMarin Pharmaceutical Price Performance

BMRN opened at $61.73 on Friday. The firm has a market capitalization of $11.86 billion, a P/E ratio of 34.68, a PEG ratio of 0.54 and a beta of 0.26. The stock has a fifty day moving average of $58.91 and a 200-day moving average of $56.18. The company has a quick ratio of 3.10, a current ratio of 5.21 and a debt-to-equity ratio of 0.10. BioMarin Pharmaceutical Inc. has a 12-month low of $50.76 and a 12-month high of $73.51.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Institutional investors and hedge funds have recently modified their holdings of the business. CIBC Private Wealth Group LLC increased its position in BioMarin Pharmaceutical by 38.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock worth $39,000 after buying an additional 179 shares during the last quarter. Northwestern Mutual Investment Management Company LLC boosted its stake in shares of BioMarin Pharmaceutical by 0.4% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 42,982 shares of the biotechnology company’s stock worth $2,554,000 after acquiring an additional 183 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of BioMarin Pharmaceutical by 7.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,741 shares of the biotechnology company’s stock valued at $163,000 after acquiring an additional 195 shares during the last quarter. Sittner & Nelson LLC increased its holdings in shares of BioMarin Pharmaceutical by 6.9% during the 2nd quarter. Sittner & Nelson LLC now owns 3,100 shares of the biotechnology company’s stock valued at $170,000 after acquiring an additional 200 shares during the last quarter. Finally, Grandfield & Dodd LLC raised its stake in shares of BioMarin Pharmaceutical by 1.2% in the 3rd quarter. Grandfield & Dodd LLC now owns 18,967 shares of the biotechnology company’s stock valued at $1,027,000 after acquiring an additional 217 shares in the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

BioMarin Pharmaceutical News Summary

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Sanford C. Bernstein published a bullish forecast calling for strong price appreciation for BMRN, which can lift investor expectations ahead of upcoming catalysts. Sanford C. Bernstein Forecast
• Positive Sentiment: Wells Fargo flagged BMRN as an attractive buy ahead of the Transcon‑CNP PDUFA decision, highlighting regulatory upside as a near‑term positive catalyst. Wells Fargo note
• Neutral Sentiment: Coverage pieces analyzing recent share rebound and DCF upside present valuation arguments but offer no clear catalyst; useful for investors modeling scenarios but not an immediate price driver. Valuation/DCF analysis
• Neutral Sentiment: Reported short‑interest data is effectively zero and contains apparent data errors (showing increases of “NaN”); this appears to be a reporting glitch and does not signal a meaningful short squeeze or surge in bearish positioning. (data entries dated Feb 26–27)
• Negative Sentiment: EVP Gregory Friberg sold 6,326 shares for roughly $382k at an average $60.38 on Feb. 26 — an insider sale that can weigh on sentiment, especially given the size relative to his remaining stake. Insider sale filing
• Negative Sentiment: HC Wainwright published a pessimistic forecast for BMRN, which could pressure sentiment among more risk‑sensitive investors. HC Wainwright note
• Negative Sentiment: Oppenheimer lowered its price target to $95, a cut that may temper upside expectations despite other bullish targets — contributes to mixed analyst messaging. Oppenheimer target cut

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on BMRN shares. Barclays started coverage on shares of BioMarin Pharmaceutical in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $80.00 price target for the company. Tudor Pickering set a $88.00 target price on shares of BioMarin Pharmaceutical in a research note on Monday, November 3rd. Leerink Partners cut shares of BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $82.00 to $60.00 in a report on Wednesday, December 3rd. Wells Fargo & Company increased their price objective on BioMarin Pharmaceutical from $70.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Finally, Sanford C. Bernstein lifted their price objective on BioMarin Pharmaceutical from $90.00 to $94.00 and gave the company an “outperform” rating in a research report on Wednesday. Fifteen analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and a consensus target price of $87.71.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.